Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 04, 2024, titled "Zydus receives tentative approval from USFDA for Azilsartan Medoxomil Tablets, 40 mg and 80 mg".
Press Release Jul 04 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Azilsartan Medoxomil Tablets. The tablets are indicated for treating hypertension and will be manufactured in Ahmedabad. The press release provides details about the approval and the drug's market potential in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jun 28 2024
- Press Release Jun 14 2024
- Press Release May 24 2024
- Press Release May 22 2024
- Press Release May 17 2024
Later from Zydus Lifesciences
- Press Release Jul 10 2024
- Press Release (Revised) Jul 10 2024
- Press Release Jul 17 2024
- Press Release Jul 19 2024
- Zydus Lifesciences Limited Press Release Jul 22 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences